ProCE Banner Activity

CME

Biomarker-Driven Lung Cancer Care: Application of New Standards and the Latest Research

Multimedia
In this on-demand webcast from a live symposium, oncology experts Todd M. Bauer; MD, Narjust Duma, MD; and Karen L. Reckamp, MD, MS discuss current and emerging data on biomarker testing and targeted therapy for the treatment of patients with NSCLC.

Physicians: Maximum of 1.75 AMA PRA Category 1 Credits

Released: June 07, 2022

Expiration: June 06, 2023

No longer available for credit.

Share

Faculty

Todd M. Bauer

Todd M. Bauer, MD

Senior Investigator, Greco-Hainsworth Centers for Research
Tennessee Oncology, PLLC
Nashville, Tennessee

Narjust Florez

Narjust Florez, MD

Associate Director of The Cancer Care Equity Program
Thoracic Medical Oncologist, Dana-Farber Cancer Institute
Assistant Professor of Medicine
Harvard Medical School
Associate Editor
JAMA Oncology
Boston, Massachusetts

Karen L. Reckamp

Karen L. Reckamp, MD, MS

Associate Professor
Medical Oncology and Therapeutics Research
City of Hope Comprehensive Cancer Center
Duarte, California

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Amgen, Inc.

Lilly

Novartis Pharmaceuticals Corporation

Turning Point Therapeutics Inc

Target Audience

This educational program is intended for medical oncologists and other healthcare professionals who treat patients with NSCLC.

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Plan individualized treatment strategies for patients with advanced NSCLC based on available evidence, expert recommendations, and tumor molecular profile
  • Discuss the practical aspects of biomarker testing and interpretation, including benefits/ limitations of different testing methodologies/platforms/assays, along with racial, age, and socioeconomic disparities
  • Assess all patients with advanced NSCLC for appropriate currently available biomarkers to guide treatment selection and clinical trial eligibility
  • Summarize the available data and expert recommendations to determine which biomarkers should be tested in your patients with lung cancer

Disclosure

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Faculty Disclosure

Primary Author

Todd M. Bauer, MD

Senior Investigator, Greco-Hainsworth Centers for Research
Tennessee Oncology, PLLC
Nashville, Tennessee

Todd M. Bauer, MD, has disclosed that he has received funds for research support paid to his institution from AbbVie, Aileron, Amgen, ARMO, Astellas, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Calithera, Clovis, Daiichi Sankyo, Deciphera, Five Prime, Foundation Medicine, Genentech/Roche, GlaxoSmithKline, Ignyta, Immunocore, Immunogen, Incyte, Jacobio, Janssen, Karyopharm, Kolltan, Leap, Lilly, Loxo, MabVax, MedImmune, Medpacto, Merck, Merrimack, Millennium, Mirati, Moderna, Novartis, Onyx, Pfizer, Peleton, Phosplatin Therapeutics, Principa Biopharma, Roche, Sanofi, Stemline, Takeda, and Top Alliance BioScience; consulting fees from Blueprint Medicines, Exelixis, Ignyta, Guardant Health, Lilly, Loxo, Merck, Moderna, and Pfizer; fees for non-CME/CE services from Astellas, AstraZeneca, Celgene, Clovis Oncology, EMD Serono, Genentech, Lilly, Merck, Novartis, Pharmacyclics, Pfizer, and Sysmex; and has served on a speakers’ bureau for Bayer.

Narjust Florez, MD

Associate Director of The Cancer Care Equity Program
Thoracic Medical Oncologist, Dana-Farber Cancer Institute
Assistant Professor of Medicine
Harvard Medical School
Associate Editor
JAMA Oncology
Boston, Massachusetts

Narjust Duma, MD, has disclosed that she has received consulting fees from AstraZeneca, BMS, DSI, Merck, Mirati, Neogenomics, and Pfizer.

Karen L. Reckamp, MD, MS

Associate Professor
Medical Oncology and Therapeutics Research
City of Hope Comprehensive Cancer Center
Duarte, California

Karen L. Reckamp, MD, MS, has disclosed that she has received consulting fees from Amgen, AstraZeneca, Blueprint, Daiichi Sankyo, EMD Serono, Genentech, GlaxoSmithKline, Janssen, Lilly, Merck KGA, Mirati, Seattle Genetics, Takeda, and Tesaro and funds for research support paid to her institution from Blueprint, Calithera, Daiichi Sankyo, Elevation Oncology, Genentech, and Janssen.

Staff Disclosure

Staff

Gordon Kelley,

Clinical Editor
Clinical Care Options, LLC

Gordon Kelley has no relevant conflicts of interest to report.

Krista Marcello,

Associate Managing Editor

Krista Marcello has no relevant conflicts of interest to report.

Jim Mortimer,

Product Director, Hematology/Oncology
Clinical Care Options, LLC

Jim Mortimer has no relevant conflicts of interest to report.

Kevin Obholz, PhD

Editorial Director, Hematology/Oncology

Kevin Obholz, PhD has no relevant conflicts of interest to report.

Timothy A. Quill, PhD

Senior Managing Editor

Timothy A. Quill, PhD has no relevant conflicts of interest to report.

Kristen Rosenthal, PhD

Clinical Editor

Kristen Rosenthal, PhD, has no relevant conflicts of interest to report.

Instructions for Credit

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 1.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Additional Information

Participation in this self-study activity should be completed in approximately 1.75 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from June 07, 2022, through June 06, 2023:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Program Medium

This program has been made available online.


Goal


The goal of this program is to improve the knowledge and competence of learners to optimally assess biomarkers and then effectively and safely integrate novel agents into their practice for patients with NSCLC.